• MBRX shares plunged after the company announced interim results from its Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia, which did not achieve statistical significance.
  • Despite the lack of statistical significance, both Annamycin treatment arms showed higher remission rates (36%-43%) compared to the control group (12%), leading the independent monitoring committee to recommend continuing the study.
  • The company also disclosed a $2.7 million capital raise from recent warrant exercises, which may contribute to investor concerns regarding dilution.